CMI 980

Drug Profile

CMI 980

Latest Information Update: 23 Aug 2002

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Class Analgesics
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
  • 24 Feb 1999 CytoMed has been wholly acquired by LeukoSite
  • 26 Nov 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top